Your new post is loading...
"The incidence of melanoma is increasing worldwide. Advances in targeted agents and immunotherapy have improved outcomes in metastatic disease, but biomarkers are required to optimize treatment. We determined the prevalence of circulating tumor cells (CTCs) and explored their utility as prognostic and pharmacodynamic biomarkers..."
Via Cancer Commons
Khoja L, Lorigan P, Zhou C, Lancashire M, et al. J Invest Dermatol. Jun 2013.